0
Array BioPharma Lung-Cancer Treatment Misses Primary Goals – Wall Street Journal
|
Array BioPharma Lung-Cancer Treatment Misses Primary Goals
Wall Street Journal Array BioPharma Inc.'s (ARRY) treatment for a certain type of metastatic nonsmall cell lung cancer with a certain type of mutation failed to meet its primary endpoint in a Phase II study in combination with chemotherapy. The biopharmaceutical company's … Topline Results: A Randomized Phase 2 Study of Selumetinib in Patients with … |





